Hemophagocytic lymphohistiocytosis: 2026 so far

Evidence expanded from reports to pediatric trial data.

In the months covered, ruxolitinib was described not only as salvage/add-on therapy (treatment used after other options, or added on) but also as the backbone of pediatric regimens. April described a single-center, non-randomized comparison where a response-guided ruxolitinib-based approach reached complete responses earlier and used less early glucocorticoid/etoposide exposure than HLH-94, with similar 12-month survival and reported safety in that comparison. June then added a prospective pediatric trial (a planned study that follows patients forward in time) reporting rapid early stabilization of inflammation markers and complete response by 8 weeks in all newly diagnosed children, with less favorable outcomes in some relapsed/refractory primary HLH. This means that, so far in 2026, ruxolitinib-based strategies were described more often for pediatric HLH, but the comparisons are still mostly non-randomized and may depend on the specific center and setting.

Research covered in: April 2026, June 2026

More trigger-specific targeting appeared in EBV-driven settings.

In the months covered, reports more often linked targeted drugs to specific drivers of HLH, especially EBV biology and interferon signaling (immune communication proteins that can amplify inflammation). April highlighted rituximab-containing regimens in EBV-HLH when EBV involved B lymphocytes (a type of white blood cell), with remission in most patients and EBV-DNA often becoming negative. It also described a very small adult series using a PD-1 inhibitor (a drug that changes immune braking signals), sintilimab, sometimes with ruxolitinib, with mixed outcomes and no severe drug-related side effects observed in that small group. Emapalumab (interferon-gamma blockade, meaning it blocks a strong inflammation signal) appeared repeatedly as a way to control inflammation when standard chemotherapy was avoided or as bridge-to-transplant therapy (used to stabilize disease until transplant). Examples included a post-liver transplant pediatric EBV-HLH case with severe liver dysfunction where etoposide was avoided, and a small genetically confirmed primary HLH cohort where most children proceeded to HSCT (hematopoietic stem cell transplant, a bone marrow or stem cell transplant) after rapid control. This means the months covered more often framed the question as which targeted drug fits the suspected trigger or immune pathway, but most evidence was still retrospective, from small cohorts, or from individual cases.

Research covered in: February 2026, April 2026, May 2026

Cohorts linked active HLH therapy to higher remission and survival.

In the months covered, cohort data connected outcomes to whether treatment went beyond supportive care alone (care like fluids, antibiotics, and general medical support). In May, a multicenter study of 162 people reported higher response rates with combination regimens than with anti-infective/supportive treatment alone, and use of IVIG (intravenous immunoglobulin, pooled antibodies given by vein) or chemotherapy was linked with survival. A separate pediatric cohort (110 children with secondary HLH) reported high remission in EBV-HLH treated with HLH-94/04-style chemotherapy. Case reports across months showed that autoimmune-related HLH/MAS (macrophage activation syndrome, a severe immune flare) could range from rapid improvement with targeted immunomodulation (immune-calming treatment), such as steroids with anakinra in one lupus case, to severe CNS involvement with only partial recovery despite treatment escalation, or refractory disease in a different patient. This means that, so far in 2026, real-world data continued to support that many HLH situations needed active immune-calming and/or chemotherapy-based treatment, while results still varied a lot depending on the trigger and complications.

Research covered in: May 2026, June 2026, August 2026

Multiple cohorts reinforced organ-complication markers as key risks.

In the January-September reports, higher short-term risk repeatedly tracked with organ complications and routine lab signs of organ stress, rather than any single trigger label. January and later months repeatedly linked disseminated intravascular coagulation (DIC, widespread abnormal clotting and bleeding risk) and CNS involvement with higher death risk in secondary HLH, and multiple groups proposed short-term risk scores using routine labs. By September, additional adult cohorts linked higher bilirubin (a bile-related blood test) and alkaline phosphatase in one cohort to higher early in-hospital death in secondary HLH. They also linked peritoneal effusion at diagnosis (fluid in the belly) to much shorter survival even after accounting for other factors. This means the months covered strengthened the pattern that clinicians often watch clotting tests, liver and bile markers, and neurologic involvement as major severity signals when deciding how closely to monitor someone.

Research covered in: January 2026, February 2026, May 2026, June 2026, September 2026

More work combined labs, immune tests, and biopsies.

In the months covered, several studies stressed that no single test reliably identifies HLH or its cause, and that HLH can be missed during a hospital stay. July reported an adult hospital cohort where some patients meeting HLH criteria were only identified after discharge, with higher mortality than those diagnosed during admission. From May to August, case-based work repeatedly showed that PET-CT-guided biopsy (a scan that helps choose where to biopsy), repeat pathology review (a second look at tissue under the microscope), bronchoalveolar lavage flow testing (immune cell testing on fluid washed from the lungs), or transjugular liver biopsy (a liver biopsy done through a neck vein) could uncover an underlying lymphoma or infection driver. September added prospective and retrospective models (forward-looking and look-back studies) combining routine labs with cytokines (immune signaling proteins), lymphocyte subsets (types of immune cells), EBV DNA, and sometimes genetic testing; performance was often strong in narrow settings, such as EBV-focused pediatric tools, but still required external validation. This means the months covered supported a combine-tests plus targeted sampling approach to reduce missed diagnoses and better pin down triggers, while most tools still appeared specific to certain centers.

Research covered in: May 2026, June 2026, July 2026, August 2026, September 2026